Premium
The current role of clinical flow cytometry in the evaluation of mature B‐cell neoplasms
Author(s) -
Seegmiller Adam C.,
Hsi Eric D.,
Craig Fiona E.
Publication year - 2019
Publication title -
cytometry part b: clinical cytometry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.646
H-Index - 61
eISSN - 1552-4957
pISSN - 1552-4949
DOI - 10.1002/cyto.b.21756
Subject(s) - flow cytometry , current (fluid) , cancer research , medicine , biology , pathology , oncology , immunology , engineering , electrical engineering
Flow cytometry (FC) has a well‐established role in the diagnostic evaluation of mature B‐cell neoplasms. Effective assessment for lineage associated antigens, aberrant antigen expression, and immunoglobulin light chain restriction requires a well‐designed, optimized, and controlled FC assay. However, it is important for hematopathologists to know when flow cytometry has a more limited role, and other modalities, such as immunohistochemistry, cytogenetic and molecular testing, are more important. This review will discuss the features of an optimal FC assay for the evaluation of mature B‐cell neoplasms, and the current role of FC in the diagnosis and sub‐classification, prognostic assessment, identification of therapeutic targets, and assessment for disease response to therapy. © 2018 International Clinical Cytometry Society